An observational study in Adherence to Glaucoma Therapy, sponsored by Laboratoires Thea. Recruiting at 15 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Laboratoires Thea · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Glaucoma with a site in Italy — 7 open to participants now, 8 under way, 1 of them phase 3. Glaucoma · Italy.
Among the 53 studies in Glaucoma with a site in Italy, this one is the 5th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2025, is one of 13 observational ones, and was the 50th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →7 of the 53 studies in Glaucoma with a site in Italy are open now. Recruiting first, the newest first:
Centervue SpA · Sites in Italy
Ages 40–90
Fondazione G.B. Bietti, IRCCS · Sites in Italy
Ages 18+
Mario Stirpe · Sites in Italy
Ages 18+
Mario Stirpe · Sites in Italy
Ages 18+ · Healthy volunteers
Association for Innovation and Biomedical Research on Light and Image · Sites in Italy, Germany, Spain and 2 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 7 · Phase 4 14
First in 1993; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 101 across 386 observational studies indexed under Glaucoma.
Median enrollment 64 across the 39 interventional studies, 200 across the 13 observational. Of the 38 that completed or were terminated, 6 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 53 have an industry lead sponsor. The 10 most frequent:
Laboratoires Thea is the lead sponsor of 64 studies on the registry; 6 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Laboratoires Thea has 9 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Glaucoma with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07006194Università degli Studi 'G. d'Annunzio' Chieti e PescaraNicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP) | 2026-12-31 |
| NCT07206628Laboratoires TheaReal-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP® | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 53 studies in Glaucoma with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this real-life, national, multicentre, prospective clinical investigation is to describe the adherence rate over time in patients with glaucoma or OHT already treated with IOP-lowering eye drops using connected device CONNECTDROP®
The main questions it aims to answer are:
Participants will use the connected device CONNECTDROP® associated with the smartphone application on a daily basis.
Glaucoma or OHT patients from hospital and/or private practice
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adherence rate over time in patients with glaucoma or OHT already treated with IOP-lowering eye drops in EASYGRIP® bottle clipped with CONNECTDROP®
Assessment of the mean annual adherence rate, defined as the percentage of the prescribed doses actually taken by the patient (i.e. at least 2 instillations per day).
Time frame: From enrollment to the end of the study at 12 months
Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.
Of 135 observational studies under Glaucoma, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 208. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.